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  A
ge-related macular disease 
(AMD) occurs most frequently 
in people aged 60 years and 
older and affects the central part 
of the retina, causing distortion or 
loss of central vision. The disease 
is the leading cause of blindness in 
people aged 60 years and older in the 
developed world and causes milder 
visual loss in a much greater number 
(about 25 percent of people aged 
60 years and older in the developed 
world have some degree of visual loss 
because of AMD). AMD generally 
involves both eyes, although they may 
not be affected at the same time or to 
the same degree. 
    There are two forms of AMD: dry and 
wet. About 90 percent of patients with 
AMD have the dry atrophic type, for 
which there is currently no treatment, 
while 10 percent have wet AMD. Wet 
AMD causes the most severe visual loss 
and is the most aggressive form of the 
disease. In the wet form, choroidal 
blood vessels grow into the retina 
(choroidal neovascularisation [CNV]) 
but do not have the characteristic tight 
barriers of normal retinal blood vessels 
and so leak ﬂ  uid into the retina. Such 
leakage often occurs under the central 
part of the retina—the macula—which 
is needed for visual detail. Scar tissue 
follows and leads to permanent severe 
visual loss. 
    In recent years, new forms of 
treatment for wet AMD have come 
into clinical practice following clinical 
trials. These new treatments are: (1) 
vitamins (the Age Related Eye Disease 
Study found that taking high levels of 
antioxidants and zinc can reduce the 
risk of developing advanced AMD by 
about 25 percent [1]);  photodynamic 
therapy; and  the most recently 
developed treatment, anti–vascular 
endothelial growth factor (anti-VEGF), 
which, when injected into the vitreous, 
has been helpful in preventing further 
visual loss and new vessel regression 
[2]. 
    A Mouse Model of CNV
    In a study published in   PLoS Medicine  , 
Apte et al. examined the role of 
the macrophage component of the 
inﬂ  ammatory response in CNV [3]. 
They used a mouse model in which 
CNV was induced in the eye with laser 
burns. In this mouse model, they 
looked at the possible role in CNV 
formation of the anti-inﬂ  ammatory 
cytokine IL-10, which inhibits T cell 
and macrophage functions.
    The researchers found that mice 
that were deﬁ  cient in IL-10 (  IL-10−/−  
mice) had increased inﬂ  ammation 
and decreased amounts of CNV 
compared with wild-type mice. Systemic 
neutralisation of IL-10 in the wild-type 
mice produced a similar response; that 
is, neutralisation signiﬁ  cantly reduced 
the laser-induced CNV in the wild-type 
mice. Intraocular injection of IL-10 in 
the   IL-10−/−  mice signiﬁ  cantly increased 
the amount of neovascularisation to the 
level of the wild-type mice despite the 
reduced inﬂ  ux of macrophages.
    The authors hypothesise that the 
effects of IL-10 in their animal model 
are most likely due to the increased 
inﬂ  ammation seen in IL-10–deﬁ  cient 
animals. They suggest that these results 
offer a novel approach to therapy in 
that IL-10 could be inhibited locally 
within the eye. Initially this treatment 
would be directed at patients with 
active CNV to limit or reverse vision 
loss, but, the authors suggest, it could 
be also used as a preventative therapy 
in patients who are at high risk of 
developing CNV. 
    Current Treatments for CNV
    CNV in the context of AMD is currently 
treated by laser therapy—either with an 
argon laser if the CNV is not sub-foveal, 
or with photodynamic therapy if the 
CNV is sub-foveal. More recently, anti-
VEGF repeatedly injected directly into 
the vitreous cavity in the eye has been 
more successful in controlling CNV 
and is now used in clinical practice. 
Different types of anti-VEGF are 
currently being used: pegaptanib (anti-
VEGF aptamer) is licensed for clinical 
use, and ranibizumab (anti-VEGF 
fragment) is about to be licensed. 
Bevacizumab, a full length anti-
VEGF antibody, is rapidly becoming 
popular in clinical practice and has 
shown impressive outcomes, albeit in 
uncontrolled trials [2]. 
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    Could the Anti-IL-10 Approach 
Be More Effective? 
    In Apte and colleagues’ study [3], the 
researchers did not inject anti-IL-10 
directly into the eye of the wild-type 
mouse to see if it had beneﬁ  cial effects 
on CNV. Instead, the researchers 
inferred beneﬁ  t from the experiments 
described above. Also they did not 
speciﬁ  cally study any preventative 
effects of anti-IL-10 upon CNV. Do 
their results provide data to support 
their ideas about the disease in 
humans? Is the biology of IL-10 in 
humans sufﬁ  ciently understood, such 
that if we inhibit it the same predictable 
response will occur in all individuals in 
all situations? 
    In humans, corticosteroids have 
an impressive anti-inﬂ  ammatory and 
anti-VEGF effect, and yet one of the 
ways they work is by up-regulating IL-
10 production. Such up-regulation 
has also been shown to occur in the 
eye [4].   IL-10−/−  mice are known to 
have higher corticosteroid levels 
in response to acute immune and 
physiologic stress [5] and are unlikely 
to have “normal” immunity. Therefore, 
Apte and colleagues need to repeat 
their experiments inducing CNV by 
laser treatment in wild-type mice and 
injecting anti-IL-10 into the eye to see if 
it reduces CNV.
    In experimental autoimmune 
encephalomyelitis, IL-10 is thought to 
be the major cytokine for recovery. The 
source of IL-10 includes B cells thought 
to be from the peripheral lymphoid 
organs and from CD4+ CD25+ T cells 
[6], and yet in Apte and colleagues’ 
study the researchers looked at only 
macrophages. IL-10 is produced by a 
variety of cell types but also is thought 
to be inhibitory for most cells and 
signalling pathways, with the exception 
of myoﬁ  broblasts [7]. However, in a 
skin-culture system IL-10 was found 
to down-regulate collagen synthesis 
[8], so if anti-IL-10 were given when 
active neovascularisation was occurring, 
healing, closure of the new vessels, and 
scarring could be increased, causing 
more of a problem. 
  Further  Unanswered  Questions
    Patients may vary in the amount of 
inﬂ  ammation associated with CNV. 
Does a patient aged 55 years, for 
example, have a different inﬂ  ammatory 
response from a patient aged 80 
years? Are variations in the cellular 
mix in the choroid and retina going 
to vary the effect of giving anti-IL-
10? Compounding this, patients 
have different balances of cytokines, 
and some IL-10 cytokine gene 
polymorphisms vary the amount of IL-
10 produced to any given stimulus [9]. 
This may mean that in some patients 
the amount of IL-10 produced locally 
is low and in others it is high, which 
will also apply to other cytokines in the 
inﬂ  ammatory area.
    Other cell types and cytokines 
present, and the balance of cytokines, 
may vary between individuals, yet it is 
not possible to know this by clinical 
examination of the patient. In terms of 
preventing visual loss, does short-term 
administration of anti-IL-10 predict the 
effects of long-term administration? 
Does acute disease induction give the 
same phenotype of the chronic disease 
process? Would it have the same effect 
if given before CNV has occurred, 
when the cellular mix in the choroid 
and retina is likely to be different? 
Injecting anti-cytokines into the eye 
to prevent disease is an interesting 
approach, but Apte and colleagues’ 
study does not provide any data to show 
that it might be useful in prevention 
of CNV, and the question of long-term 
toxicity to the retina is paramount. 
  Conclusion
    Apte and colleagues’ preliminary 
ﬁ  ndings are intriguing, but they are 
too early to have direct relevance to 
treating humans. In asthma, studies 
in mice indicated that IL-5 was a key 
cytokine, but its inhibition had no 
effect on bronchiolar constriction in 
humans [10]. Animal models may 
help in understanding the interactions 
of the components of a given disease 
response, but the situation can be 
completely different in humans.   
  References
    1.  Age-Related Eye Disease Study Research Group 
(2001) A randomized, placebo-controlled, 
clinical trial of high-dose supplementation with 
vitamins C and E, beta carotene, and zinc for 
age-related macular degeneration and vision 
loss: AREDS report no. 8. Arch Ophthalmol 
119: 1417–1436.
    2.  Michels S, Schmidt-Erfurth U, Rosenfeld 
PJ (2006) Promising new treatments for 
neovascular age-related macular degeneration. 
Expert Opin Investig Drugs 15: 779–793. 
    3.  Apte RS, Richter J, Herndon J, Ferguson TA 
(2006) Macrophages inhibit neovascularization 
in a murine model of age-related macular 
degeneration. PLoS Med 3: e310. 
DOI:10.1371/journal.pmed.0030310
    4.  Muhaya M, Calder VL, Towler HM, Jolly G, 
McLauchlan M, et al. (1999) Characterization 
of phenotype and cytokine proﬁ  les of T cell 
lines derived from vitreous humour in ocular 
inﬂ  ammation in man. Clin Exp Immunol 116: 
410–414. 
    5.  Koldzic-Zivanovic N, Tu H, Juelich TL, Rady 
PL, Tyring SK, et al. (2005) Regulation of 
adrenal glucocorticoid synthesis by interleukin-
10: A preponderance of IL-10 receptor in the 
adrenal zona fasciculata. Brain Behav Immun. 
E-pub ahead of print. 
    6.  McGeachy MJ, Anderton SM (2005) 
Cytokines in the induction and resolution of 
experimental autoimmune encephalomyelitis. 
Cytokine 32: 81–84.
    7.  Andoh A, Zhang Z, Inatomi O, Fujino 
S, Deguchi Y, et al. (2005) Interleukin-
22, a member of the IL-10 subfamily, 
induces inﬂ  ammatory responses in colonic 
subepithelial myoﬁ  broblasts. Gastroenterology 
129: 969–984. 
    8.  Wangoo A, Laban C, Cook HT, Glenville 
B, Shaw RJ (1997) Interleukin-10- and 
corticosteroid-induced reduction in type I 
procollagen in a human ex vivo scar culture. 
Int J Exp Pathol 78: 33–41. 
    9.  Crawley E, Kay R, Sillibourne J, Patel P, 
Hutchinson I, et al. (1999) Polymorphic 
haplotypes of the interleukin-10 5' ﬂ  anking 
region determine variable interleukin-10 
transcription and are associated with particular 
phenotypes of juvenile rheumatoid arthritis. 
Arthritis Rheum 42: 1101–1108. 
    10. O’Byrne PM, Inman MD, Parameswaran K 
(2001) The trials and tribulations of IL-5, 
eosinophils, and allergic asthma. J Allergy Clin 
Immunol 108: 503–508. 
August 2006  |  Volume 3  |  Issue 8  |  e364